Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Prophylaxis of Venous Thrombo-Embolism in Cancer Patients Under Palliative Care

This study has been terminated.
Information provided by:
University Hospital, Geneva Identifier:
First received: March 15, 2006
Last updated: NA
Last verified: December 2005
History: No changes posted
To determine the efficacy and to measure the complications of prophylactic anticoagulation using low-molecular weight heparin in adult cancer patients under palliative care

Condition Intervention Phase
Venous Thromboembolism
Drug: nadroparin
Phase 4

Study Type: Observational
Study Design: Observational Model: Defined Population
Time Perspective: Longitudinal
Time Perspective: Prospective

Resource links provided by NLM:

Further study details as provided by University Hospital, Geneva:

Study Start Date: January 2001
Estimated Study Completion Date: July 2002

Ages Eligible for Study:   Child, Adult, Senior
Genders Eligible for Study:   Both

Inclusion Criteria:

  • Cancer patients in palliative care
  • Patients fully informed about their condition
  • Signed informed consent
  • No exclusion criteria

Exclusion Criteria:

  • Absence of advanced cancer
  • Cancer previously cured
  • Venous thromboembolism diagnosed within 6 months prior to inclusion
  • Absence of discerning capacity
  • Active anti-thrombotic treatment with heparins or coumarines
  • Thrombocytopenia <50G/l
  • PTT >45sec
  • TP<35%
  • Active bleeding
  • Renal failure <20ml/min
  • Past history of heparin-induced thrombocytopenia
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00303407

Center of Continuous Care, chemin de la Savonnière
Collonge-Bellerive (Geneva), Geneva, Switzerland, 1245
Sponsors and Collaborators
University Hospital, Geneva
Principal Investigator: Catherine Weber, MD Center of Continuous Care, chemin de la Savonnière 11, CH-1245 Collonge-Bellerive
  More Information

Publications: Identifier: NCT00303407     History of Changes
Other Study ID Numbers: SPOT 99/54 
Study First Received: March 15, 2006
Last Updated: March 15, 2006
Health Authority: Switzerland: Ethikkommission

Additional relevant MeSH terms:
Venous Thromboembolism
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action processed this record on October 25, 2016